You are NOT What You Eat! Functional Paleo Video #2
Did you know that 60% of the American population suffers from at least one system of poor digestion -- gas, bloating, belching, heartburn, constipation, diar...
By: Paleohacks
Read the original here:
You are NOT What You Eat! Functional Paleo Video #2 - Video
6 months post medial closing wedge Distal Femoral Osteotomy
By: hampshireknee
Read the original post:
6 months post medial closing wedge Distal Femoral Osteotomy - Video
AMU SILVER JUBILEE CELEBRATION
for more news plz visit our website http://www.aligarhkhabar.com.
By: Aligarh Khabar
XF PMP was developed in partnership with the Pioneer Valley Life Sciences Institute (PVLSI), a joint venture of Baystate Medical Center and the University of Massachusetts Amherst, with the dual missions of biomedical research and economic development. The technology was exclusively licensed to Seahorse Bioscience by UMass Amherst and Baystate Health, the parent organization of Baystate Medical Center.
XF PMP can be used with the Seahorse XF(e) Extracellular Flux Analyzer, an instrument for measuring cell metabolism, in real-time, in a microplate. The reagent was developed for XF technology in part by Dr. Nagendra Yadava, the John Adams Investigator at PVLSI; and Dr. Alejandro Heuck, Ph.D., an Assistant Professor of Biochemistry and Molecular Biology at UMass Amherst.
"In the development of this potent new tool in biomedical analysis, we see the tremendous potential of collaborations between clinical and academic researchers and ingenuitive companies like Seahorse," said Richard Friedberg, M.D., Ph.D., chair of Pathology and chair of the Intellectual Property Committee at Baystate Health, who represented Baystate in working with Seahorse and UMass to establish the licensing agreement.
XF PMP creates pores in the cell plasma membrane, and delivers a degree of precision and ease-of-use that has not been available to scientists researching cell metabolism. A key element of XF PMP is the ability to assess mitochondrial function in adherent monolayers of permeabilized cells without damaging the mitochondrial membrane. By doing so, XF PMP enables metabolic substrates, compounds, and small proteins that otherwise would not cross the plasma membrane to reach the mitochondria.
"Seahorse's new XF Plasma Membrane Permeabilizer [PMP] enabled us to demonstrate that clinically-relevant concentrations of thiazolidinediones, a class of insulin sensitizers that includes Actos, specifically inhibited the mitochondrial pyruvate carrier, a protein at the hub of cellular metabolism. The simplicity and reliability of XF PMP made it easy to interrogate the mitochondrial function of small clinical samples and genetically modified cells without mitochondrial isolation, experiments that are traditionally difficult or impossible. Our work is providing a new understanding of the mechanism of action of an important class of drugs, and opens a new avenue for the development of drugs to treat diseases including type 2 diabetes, neurodegenerative disease, and heart failure," stated Anne N. Murphy, Ph.D., Associate Professor of Pharmacology at University of California, San Diego.
About Seahorse Bioscience Seahorse Bioscience provides industry-leading analytical instruments, cell-based assay kits, and consumable labware products for biological research and drug discovery. Scientists worldwide use these tools to advance their research in understanding the role of mitochondrial dysfunction in cancer, neuroscience, immunology, obesity, diabetes, ageing, cardiovascular function, and safety toxicity. Seahorse is headquartered in Billerica, Massachusetts; has its manufacturing facilities in Chicopee, Massachusetts; and regional headquarters in Copenhagen and Shanghai. For more information visit: http://www.seahorsebio.com.
About Baystate Medical Center Baystate Medical Center is an academic, research and teaching hospital that serves as the western campus of Tufts University School of Medicine. It is the major referral care center and only Level 1 trauma center for western Massachusetts, and is home to one of New England's busiest emergency rooms. One of Thomson Reuters/Truven Health Analytics' top 50 U.S. hospitals for cardiovascular care and top 100 U.S. hospitals, Baystate Medical Center is also designated a Leapfrog Top Hospital for quality and safety, is a Magnet hospital for nursing excellence, and is a six-time winner of the Beacon Award for Critical Care Excellence. http://www.baystatehealth.org/bmc
About the University of Massachusetts Amherst The University of Massachusetts Amherst, the flagship campus of the UMass system, is one of the nation's top public research universities with 28,000 students studying in the scenic Pioneer Valley of Western Massachusetts. Celebrating its 150th anniversary in 2013, UMass Amherst offers 108 undergraduate degree programs (including six associate degrees) as well as 76 masters and 50 doctoral programs. For more information visit: http://www.umass.edu.
About the Pioneer Valley Life Sciences Institute PVLSI was created in 2002 as a joint venture of Baystate Medical Center and the University of Massachusetts Amherst, with the dual missions of biomedical research and economic development. Drawing on each of the founders as well as its own researchers, the Institute brings together physicians, scientists, and engineers to create interdisciplinary and multidisciplinary teams focused on the molecular mechanisms of disease and the development of new diagnostic and therapeutic tools. For more information visit: http://www.pvlsi.org.
Contact: Naomi Goumillout, 1-978-671-1619, ngoumillout@seahorsebio.com
Link:
Reagent aids scientists in mitochondrial dysfunction analysis.
Age Rejuvenation Centers - The Future of Healthcare | Look and Feel 20 years younger
http://www.Agerejuvenationcenters.com Age Rejuvenation Center "Do you feel sluggish or tired? Are you overweight? Are you living life to the fullest? Hormone Replac...
By: AgeRejuvenationCtrs
Go here to see the original:
Age Rejuvenation Centers - The Future of Healthcare | Look and Feel 20 years younger - Video
Bayer AG ( BAYRY ) recently presented positive results on ATX-101 at the 11th Anti-Aging Medicine World Congress (AMWC) 2013. ATX-101 is being developed for the reduction of unwanted fat deposits under the chin- submental fat (SMF).
Results from a phase IIa study showed that ATX-101 significantly and consistently reduces SMF. The level of SMF reduction was sustained in more than 90% patients who responded to treatment. Moreover, treatment satisfaction was sustained in more than 80% of these patients.
Results from another phase I pharmaco-kinetic study showed that the permanent destruction of fat cells (adipocytolysis) made by ATX-101 did not have any clinically significant impact on the serum lipid levels of the patients in the study. Notably, ATX-101 is the first injectable candidate being evaluated as a non-surgical treatment for SMF reduction in a comprehensive clinical trial setting.
In Feb 2013, Bayer presented positive results from two European phase III studies on ATX-101 at the International Master Course on Aging Skin (IMCAS). Results from the studies showed that ATX-101 reduced SMF more than placebo. ATX-101 demonstrated significant improvement in clinician-reported measurements of SMF, supported by objective caliper measurements of SMF thickness, in comparison to placebo.
Results also revealed that patients were more satisfied with their chin appearance and their treatment with ATX-101 than placebo. The candidate was well tolerated in both the studies.
We note that the studies are part of the ATX-101 clinical development program which is being conducted jointly by Bayer and Kythera Biopharmaceuticals Inc. ( KYTH ) since 2010. As per the 2010 licensing deal between the companies, Bayer acquired rights to ATX-101 in markets outside the US and Canada.
Kythera is eligible to receive tiered double-digit royalties on the sales of the drug made by Bayer outside the US and Canada. Kythera and Bayer have however collaborated to develop ATX-101 in Europe.
In Nov 2012, Kythera had reported positive interim results from a multicenter, open-label, long-term study on ATX-101. The study revealed that the candidate was well tolerated and demonstrated a similar safety profile to that observed in previous studies conducted with the candidate.
We note that Bayer suffered a huge setback last month when the company and its partner Johnson & Johnson ( JNJ ) received a second complete response letter (CRL) from the US Food and Drug Administration (FDA) for their supplemental New Drug Application (sNDA) for Xarelto (2.5 mg twice daily) for the reduction of the risk of secondary cardiovascular events in patients suffering from ACS.
The second CRL for Xarelto is a big disappointment for the company. Bayer carries a Zacks Rank #4 (Sell). The setback regarding Xarelto is primarily responsible for the bearish rank carried by the company. Cytokinetics Inc. ( CYTK ) currently looks better positioned in the pharma space carrying a Zacks Rank #1 (Strong Buy).
See the article here:
Data Presented on Bayer's ATX-101 - Analyst Blog
Background:
Reducing the production cost of, and increasing revenues from, industrial biofuels will greatly facilitate their proliferation and co-integration with fossil fuels. The cost of feedstock is the largest cost in most fermentation bioprocesses and therefore represents an important target for cost reduction. Meanwhile, the biorefinery concept advocates revenue growth through complete utilization of by-products generated during biofuel production. Taken together, the production of biofuels from low-cost crude glycerol, available in oversupply as a by-product of bioethanol production, in the form of thin stillage, and biodiesel production, embodies a remarkable opportunity to advance affordable biofuel development. However, few bacterial species possess the natural capacity to convert glycerol as a sole source of carbon and energy into value-added bioproducts. Of particular interest is the anaerobe Clostridium pasteurianum, the only microorganism known to convert glycerol alone directly into butanol, which currently holds immense promise as a high-energy biofuel and bulk chemical. Unfortunately, genetic and metabolic engineering of C. pasteurianum has been fundamentally impeded due to lack of an efficient method for deoxyribonucleic acid (DNA) transfer.
Results:
This work reports the development of an electrotransformation protocol permitting high-level DNA transfer to C. pasteurianum ATCC 6013 together with accompanying selection markers and vector components. The CpaAI restriction-modification system was found to be a major barrier to DNA delivery into C. pasteurianum which we overcame by in vivo methylation of the recognition site (5'-CGCG-3') using the M.FnuDII methyltransferase. With proper selection of the replication origin and antibiotic-resistance marker, we initially electroporated methylated DNA into C. pasteurianum at a low efficiency of 2.4 x 101 transformants mug-1 DNA by utilizing conditions common to other clostridial electroporations. Systematic investigation of various parameters involved in the cell growth, washing and pulse delivery, and outgrowth phases of the electrotransformation procedure significantly elevated the electrotransformation efficiency, up to 7.5 x 104 transformants mug-1 DNA, an increase of approximately three order of magnitude. Key factors affecting the electrotransformation efficiency include cell-wall-weakening using glycine, ethanol-mediated membrane solubilization, field strength of the electric pulse, and sucrose osmoprotection.
Conclusions:
C. pasteurianum ATCC 6013 can be electrotransformed at a high efficiency using appropriately methylated plasmid DNA. The electrotransformation method and tools reported here should promote extensive genetic manipulation and metabolic engineering of this biotechnologically important bacterium.Source:
http://www.biotechnologyforbiofuels.com/content/6/1/50
PARIS, April 8, 2013 /PRNewswire/ --
GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a 32 million Series A financing.
The financing was co-led by Novartis Venture Fund, Abingworth LLP, Versant Ventures and Index Ventures. GenSight will use the funds to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP). The lead product is expected to enter the clinic in 2013 in LHON patients.
Bernard Gilly, co-founder and CEO of GenSight is a successful bio-entrepreneur, was formerly CEO of Fovea Pharmaceuticals (which was acquired by sanofi-aventis in 2009), a partner at Sofinnova Partners and CEO of Transgene, a publicly traded gene therapy company. GenSight co-founder, Professor Jos-Alain Sahel, is Chairman of the Vision Institute in Paris. Botond Roska, a specialist in the structure and function of neural circuits at the FMI (Basel), has been pioneering the field of optogenetics. Jean Bennett, Professor of Ophthalmology, University of Pennsylvania, and also a co-founder of GenSight, has successfully conducted gene therapy trials to treat a rare retinal degeneration. The other co-founders of GenSight are Connie Cepko Professor of Genetics at Harvard (Boston), Ernst Bamberg Professor at The Max Planck Institute (Frankfurt), Luk Vandenberghe at the Schepens Eye Research Institute(Boston) and Serge Picaud at the Vision Institute (Paris).
Bernard Gilly commented: "Gene therapy is coming of age and ophthalmology is one of the most promising indications in particular because of the safety and efficacy demonstrated in certain trials. GenSight has a unique, proprietary approach to targeting the mitochondria in LHON developed by Dr Corral-Debrinsky and Jose Sahel at the Vision Institute, and exclusive access to key intellectual property from Novartis for using optogenetics to treat RP patients. Our outstanding links to leading ophthalmology physicians and scientists on both sides of the Atlantic, our strong link with the Foundation Fighting Blindness, our partnership with AFM/Genethon and our experienced management team are key to successfully moving our products through clinical developments to proof of efficacy."
"We are delighted to be working with GenSight and the other investors to assist the company in progressing its highly innovative technology and gene-based therapeutics towards the clinic. Gene therapy represents a new frontier in targeting ophthalmic diseases, and GenSight's expertise and capabilities are outstanding," said Florent Gros of Novartis Venture Fund, who will join the board of directors, along with Dr Genghis Lloyd-Harris (Abingworth) and Dr Guido Magni (Versant).
GenSight is based in Paris, France on the campus of the Vision Institute. Please visit our website http://www.gensight-biologics.com
Notes for Editors
About Novartis Venture Fund
The Novartis Venture Funds manages over $850 million in committed capital. NVF invests in companies which have the potential to change a core therapeutic field or explore new business areas that will be critical to patient care. Our primary interest is in the development of novel therapeutics and platforms as well as medical devices, diagnostics, and delivery systems. The Funds invest for financial objectives at all stages, but prefers to invest in the early-stages of company development. With ten investment professionals located in Basel, Switzerland and Cambridge, MA the team has extensive experience in pharmaceutical R&D and venture capital.
Read the rest here:
GenSight Biologics Raises €32m in a Series A Financing for Ophthalmic Gene Therapy
NY State: Most Corrupt = Least Freedom
Would the last honest politician in Albany turn off the lights mdash; or simply steal the bulbs? The ever-expanding cesspool of political corruption in New York c...
By: TheAlexJonesChannel
View post:
Freedom from Thought: how to ceace identifying with our mind - "Resting As the I Am" Meditation
Often many of experience ourselves as victims of our thoughts, unable to get away from them and unable to be at peace in their presence. We can lose sleep, b...
By: Boris Kerjner
See original here:
Our Children Are Our Freedom - Operation Paul Revere InfoWars.com Contest
Our Children Are Our Freedom - Operation Paul Revere InfoWars.com Contest Hope yall like it 🙂 http://www.infowars.com - Cheers Jimmy 🙂
By: littlejimmy95
Link:
Our Children Are Our Freedom - Operation Paul Revere InfoWars.com Contest - Video
FREEDOM TO DANCE - LAST CHANCE FOR ENTRIES
By: Alan Clarke
Link:
CQB Airsoft Action (ITA) Loski vs Freedom Fighters
LOSKI SOFTAIR KOMMANDO vs FREEDOM FIGHTERS indoor area in Arzignanio (ITALY).i #39;m using a gopro HD Hero2 in narrow mode loski softair kommando vs freedom figh...
By: Edoardo Meneguzzo
See the rest here:
Gawither - Money isn #39;t Freedom (Hans Cassonetto)
Fourth track from the "KABOOM!" EP! Follow us on facebook! http://www.facebook.com/gawither Recorded mixed by Carmelo Giacchino - Nologo Studio Mastering b...
By: GawitherBandThrash
See original here:
Vellu - Freedom (2013)
Freedom ain #39;t free http://www.facebook.com/teamunito My tricking training through 2012 and beginning of 2013. When I trick I feel free. Right now I am servin...
By: teamunito
Here is the original post:
More journalists, bloggers, musicians and other public figures are increasingly being summoned to court in an apparent crackdown on freedom of expression in Egypt and Tunisia. But they're not going without a fight.
Egyptian TV satirist Bassem Youssef, who has been compared with United States news parody show host Jon Stewart, this past week had to answer to Egyptian prosecutors over charges of insulting Islam and President Morsi. Although an Egyptian administrative court threw out a lawsuit filed by a Muslim Brotherhood lawyer seeking to ban Youssef and his satirical political show, Youssef still faces other, similar charges.
Meanwhile in Tunisia, rapper Weld El 15 was recently sentenced in absentia to two years in prison for insulting the police. The two cases point to ongoing efforts by Islamist forces to use the courts to muzzle criticism of North African governments.
The fall of dictatorial regimes after the Arab Spring apparently hasn't brought about any durable guarantees for freedom of expression. On the contrary, there seems to be an offensive against free speech in North Africa - yet this is being met with resistance, and the world is looking on.
'Judicial harassment'
Human rights groups note an increase in court cases charging religious defamation. Amnesty International researcher Diana Eltahawy cited an offensive targeting 33 activists, bloggers and politicians over the past few weeks. This represents increasing "judicial harassment" of those leveling political or societal critique, Eltahawy told DW.
This comes despite the new Egyptian constitution guaranteeing freedom of expression. Clauses about defamation opened a legal grey area that certain forces are trying to exploit to muzzle criticism, also in the form of satire.
Eltahawy pointed out that many of the legal challenges are filed by regular individuals or Islamist lawyers. Slander of political figures and denigration of religious values are the primary charges.
But the state prosecution has ultimate say in the matter, Eltahawy added. "They can make the decision not to press charges, not to refer the matters to court," she said. Though it should be defending free speech, instead "the public prosecutor is increasingly charging individuals for freely expressing themselves," Eltahawy said.
Creative expression targeted
See the rest here:
A musical group that has experienced trials and tribulations in their steadfast devotion to their faith performed in Vulcan on Saturday.
Simon Ivascu and his brother Stefan fled Romania as teenagers in the late 1990s, when they faced, upon completing high school, mandatory military service.
But freedom of worship was restricted in the army, and the boys, being conscientious Christians, refused to serve. However, this would mean several years of imprisonment and persecution, so they made the difficult decision to flee their home country, facing many dangers and hardships along the way.
Simon left Romania in 1997 while his brother had fled a few years prior. Wesley Pop, a close friend and also a member of the Freedom Singers, left about a year after Simon.
He found his way to Italy, where he stayed until 1999. During his time in Italy, Simon met up with Pop, and the two decided to leave the country together. Stefan was able to stay in Italy until 2006.
Simon and Pop paid cash to gain access to a shipping container, and their handler warned them about the trip ahead and suggested they bring certain items, including several tools that would later prove to be life saving.
Once in the container, they were locked up.
We didnt even know where it was heading, Simon told the Advocate during a phone interview on Friday. We ended up in Montreal.
But it wasnt as easy as that. Before their container was even loaded on a ship, they spent four days at a port, said Simon.
They coped with roasting temperatures inside the container, and eventually, water and food ran out. Oxygen was also running out. In order to breathe, they had to drill holes in the container and used juice box straws to get some air, he said.
Here is the original post: